Literature DB >> 1552097

Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.

P R Eisenberg1, B E Sobel, A S Jaffe.   

Abstract

Increases in thrombin activity in patients given fibrinolytic agents for acute myocardial infarction have been shown to be important in limiting the ultimate success of coronary thrombolysis. The present study was designed to determine whether increases in thrombin activity reflect, in part, activation of prothrombin accompanying thrombolysis. Plasma concentrations of prothrombin fragment 1.2, a polypeptide released when prothrombin is activated by factor Xa, were measured in 22 patients with acute myocardial infarction before and after treatment with 100 mg of recombinant tissue-type plasminogen activator (rt-PA). Concentrations of prothrombin fragment 1.2 increased from 0.83 +/- 1.1 nM (mean +/- SD) before rt-PA infusion to 1.5 +/- 1.5 nM 2 h after initiation of the infusion (p less than 0.05). After a 5,000-U intravenous dose of heparin given at the end of the infusion of rt-PA, concentrations of prothrombin fragment 1.2 decreased from 1.8 +/- 1.5 to 1.1 +/- 0.9 nM (n = 20, p less than 0.05), although values were still increased compared with concentrations before rt-PA. These results indicate that thrombin activity increases in patients given rt-PA at least in part because of activation of the coagulation system leading to activation of prothrombin. Thus, inhibition of the reactions involving coagulant proteins that lead to activation of prothrombin may be of value as conjunctive treatment to potentiate the efficacy of pharmacologic thrombolysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552097     DOI: 10.1016/0735-1097(92)90296-y

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

Review 1.  Platelet activation in acute myocardial infarction and the rationale for combination therapy.

Authors:  I Conde-Pozzi; N Kleiman
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

2.  Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.

Authors:  N S Kleiman; R P Tracy; J D Talley; K Sigmon; D Joseph; E J Topol; R M Califf; M Kitt; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

Review 3.  [STEMI guidelines 2008--Do they influence today's myocardial infarction treatment strategies in rural areas?].

Authors:  Alois Suessenbacher; Maria M Wanitschek; Jakob Doerler; Otmar Pachinger; Hannes F Alber
Journal:  Wien Med Wochenschr       Date:  2010-01

4.  Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study.

Authors:  Eric L Wallace; Susan S Smyth
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

5.  Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.

Authors:  S S Rebello; R G Bentley; S R Morgan; C J Kasiewski; V Chu; M H Perrone; R J Leadley
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.

Authors:  M S Sabatine; T M Tu; I K Jang
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

7.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

8.  Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

Authors:  P R Eisenberg; J E Siegel; D R Abendschein; J P Miletich
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

Authors:  Giuseppe De Luca; C Michael Gibson; Francesco Bellandi; Sabina Murphy; Mauro Maioli; Marko Noc; Uwe Zeymer; Dariusz Dudek; Hans-Richard Arntz; Simona Zorman; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Mariann Gyongyosi; Kurt Huber; Arnoud W J Van't Hof
Journal:  J Thromb Thrombolysis       Date:  2008-11-22       Impact factor: 2.300

Review 10.  Antithrombotic therapies in primary angioplasty: rationale, results and future directions.

Authors:  Giuseppe De Luca; Paolo Marino
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.